The use of human samples was approved by the ethics committee of the medical faculty of the University Duisburg-Essen. Nasal mucosa MSCs, further referred to as “MSCs” in this study, were obtained from the inferior nasal concha of healthy individuals (age 30-70 years) at the Department of Othorhinolaryngology, University Hospital Essen (Essen, Germany). The isolation, culture of MSCs and evaluation of differentiation potential were conducted as described before (8 (link)). MSCs were cultured in DMEM/RPMI-1640 high glucose (50%/50% v/v), supplemented with 2mM L-Glutamine, 100 IU/ml penicillin, 100 mg/ml streptomycin (all ThermoFisher Scientific, Karlsruhe, Germany) and 10% (v/v) heat-inactivated FCS (Merck/Biochrom, Berlin, Germany). All MSCs used in experiments were between passages 3-6.
Bone marrow MSCs further referred to as “bmMSCs” were kindly provided by Bernd Giebel from the Institute of Transfusion Medicine, University Hospital Essen, Germany, registered as “MSC 41.5”. BmMSCs were originally isolated from bone marrow aspirates of healthy individuals after informed consent as described before (26 (link)) and acquisition was approved by the ethics committee of the medical faculty of the University Duisburg-Essen. Phenotyping of bmMSCs used in the study was conducted in line with ISCT minimal criteria for MSCs (6 (link)), by evaluating cell-surface marker expression with flow cytometry and trilineage differentiation to validate multipotent differentiation capacity of MSCs (8 (link)). Experiments with bmMSCS were conducted within passage 4-6. BmMSCs were cultured in DMEM low glucose (PAN Biotech, Aidenbach, Germany), supplemented with 10% platelet lysate (kindly provided by the Institute of Transfusion Medicine, University Hospital Essen), 100 U/mL penicillin-streptomycin-glutamine and 5 IU/mL Heparin (Ratiopharm, Ulm, Germany).
Bone marrow MSCs further referred to as “bmMSCs” were kindly provided by Bernd Giebel from the Institute of Transfusion Medicine, University Hospital Essen, Germany, registered as “MSC 41.5”. BmMSCs were originally isolated from bone marrow aspirates of healthy individuals after informed consent as described before (26 (link)) and acquisition was approved by the ethics committee of the medical faculty of the University Duisburg-Essen. Phenotyping of bmMSCs used in the study was conducted in line with ISCT minimal criteria for MSCs (6 (link)), by evaluating cell-surface marker expression with flow cytometry and trilineage differentiation to validate multipotent differentiation capacity of MSCs (8 (link)). Experiments with bmMSCS were conducted within passage 4-6. BmMSCs were cultured in DMEM low glucose (PAN Biotech, Aidenbach, Germany), supplemented with 10% platelet lysate (kindly provided by the Institute of Transfusion Medicine, University Hospital Essen), 100 U/mL penicillin-streptomycin-glutamine and 5 IU/mL Heparin (Ratiopharm, Ulm, Germany).
Free full text: Click here
